These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34185563)

  • 1. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
    Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
    J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
    [No Abstract]   [Full Text] [Related]  

  • 2. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 3. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Park H; Jiang X; Song HJ; Lo Re V; Childs-Kean LM; Lo-Ciganic WH; Cook RL; Nelson DR
    Hepatology; 2021 Aug; 74(2):566-581. PubMed ID: 33544904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
    Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
    Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
    Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
    Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
    Ottman AA; Townsend ML; Hashem MG; Britt RB
    Ann Pharmacother; 2019 Jun; 53(6):581-587. PubMed ID: 30654625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?
    Makarenko I; Artenie A; Hoj S; Minoyan N; Jacka B; Zang G; Barlett G; Jutras-Aswad D; Martel-Laferriere V; Bruneau J
    Int J Drug Policy; 2019 Oct; 72():69-76. PubMed ID: 31010749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection.
    van Boemmel-Wegmann S; Lo Re V; Park H
    Dig Dis Sci; 2020 Nov; 65(11):3159-3174. PubMed ID: 31938995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
    Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
    Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
    Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
    Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
    Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.